Merck & Co. and Moderna maintain a decade-long collaboration on their individualized neoantigen therapy intismeran autogene, with positive Phase 3 melanoma data released in August 2026 reinforcing the partnership structure rather than prompting consolidation. Merck's recent M&A activity—such as the $6.7 billion Terns Pharmaceuticals deal and other oncology-focused acquisitions—reflects a preference for targeted pipeline additions over large-scale mergers, while differing market capitalizations, strategic priorities, and the absence of any disclosed discussions sustain the 98.8% market-implied odds against a 2026 announcement. Trader consensus aligns with observable capital allocation patterns and the economic rationale of sharing development costs and profits without full integration. Tail-risk scenarios include an unforeseen regulatory or competitive shock that could accelerate strategic reevaluation, though no such catalysts have materialized.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated1% chance
NEW
NEW
Dec 31, 2026
1% chance
NEW
NEW
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration on their individualized neoantigen therapy intismeran autogene, with positive Phase 3 melanoma data released in August 2026 reinforcing the partnership structure rather than prompting consolidation. Merck's recent M&A activity—such as the $6.7 billion Terns Pharmaceuticals deal and other oncology-focused acquisitions—reflects a preference for targeted pipeline additions over large-scale mergers, while differing market capitalizations, strategic priorities, and the absence of any disclosed discussions sustain the 98.8% market-implied odds against a 2026 announcement. Trader consensus aligns with observable capital allocation patterns and the economic rationale of sharing development costs and profits without full integration. Tail-risk scenarios include an unforeseen regulatory or competitive shock that could accelerate strategic reevaluation, though no such catalysts have materialized.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Market Opened: Aug 19, 2026, 3:58 PM ET
Volume
$425End Date
Jan 1, 2027Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration on their individualized neoantigen therapy intismeran autogene, with positive Phase 3 melanoma data released in August 2026 reinforcing the partnership structure rather than prompting consolidation. Merck's recent M&A activity—such as the $6.7 billion Terns Pharmaceuticals deal and other oncology-focused acquisitions—reflects a preference for targeted pipeline additions over large-scale mergers, while differing market capitalizations, strategic priorities, and the absence of any disclosed discussions sustain the 98.8% market-implied odds against a 2026 announcement. Trader consensus aligns with observable capital allocation patterns and the economic rationale of sharing development costs and profits without full integration. Tail-risk scenarios include an unforeseen regulatory or competitive shock that could accelerate strategic reevaluation, though no such catalysts have materialized.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425End Date
Jan 1, 2027Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck & Co. and Moderna maintain a decade-long collaboration on their individualized neoantigen therapy intismeran autogene, with positive Phase 3 melanoma data released in August 2026 reinforcing the partnership structure rather than prompting consolidation. Merck's recent M&A activity—such as the $6.7 billion Terns Pharmaceuticals deal and other oncology-focused acquisitions—reflects a preference for targeted pipeline additions over large-scale mergers, while differing market capitalizations, strategic priorities, and the absence of any disclosed discussions sustain the 98.8% market-implied odds against a 2026 announcement. Trader consensus aligns with observable capital allocation patterns and the economic rationale of sharing development costs and profits without full integration. Tail-risk scenarios include an unforeseen regulatory or competitive shock that could accelerate strategic reevaluation, though no such catalysts have materialized.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions